SPTLC1 and amyotrophic lateral sclerosis: Consequently, we demonstrated increased free sphinganine and circulating ceramide levels in the affected individuals, which aligns with the pathophysiological pattern observed in patients with early‐onset ALS carrying pathogenic SPTLC1 variants.10